Influence of rhBNP combined with sacubitril valsartan on blood lipids,hemodynamics and prognosis in patients with coronary heart disease and heart failure
10.3969/j.issn.1008-0074.2024.06.17
- VernacularTitle:rhBNP联合沙库巴曲缬沙坦对冠心病合并心力衰竭患者血脂、血流动力学及预后的影响
- Author:
Zhi-min REN
1
;
Hua CHEN
1
Author Information
1. 如皋市人民医院心血管内科,江苏如皋 226500
- Publication Type:Journal Article
- Keywords:
Coronary disease;
Heart failure;
Recombinant human brain natriuretic Peptide;
Sacubitril-valsartan
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2024;33(6):734-738
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aims to analyze the influence of recombinant human brain natriuretic peptide(rhB-NP)combined with sacubitril valsartan on blood lipids,hemodynamics and prognosis in patients with coronary heart disease(CHD)and heart failure(HF).Methods:This randomized controlled study enrolled 130 CHD+HF pa-tients admitted in Rugao People's Hospital between July 2018 and July 2021.They were divided into control group(n=65,rhBNP therapy)and combined treatment group(n=65,additional sacubitril valsartan therapy based on con-trol group),and treated for 3 months.Blood lipids,hemodynamic indexes,total effective rate,incidence of adverse reactions,prognosis after 6-month follow-up were compared between two groups.Results:The total effective rate of combined treatment group was significantly higher than that of control group(90.77％vs.70.77％,P=0.004).Compared with patients in control group after 3-month treatment,those in combined treatment group had significant lower levels of total cholesterol(TC)[(4.05±0.96)mmol/L vs.(2.97±0.93)mmol/L],triglyceride(TG)[(1.75±0.52)mmol/L vs.(1.12±0.23)mmol/L],low density lipoprotein cholesterol(LDL-C)[(3.05±0.99)mmol/L vs.(2.54±0.72)mmol/L],mean arterial pressure(MAP)[(94.73±9.23)mmol/L vs.(85.64±8.25)mmol/L]and heart rate[(91.32±7.90)beats/minvs.(82.34±8.58)beats/min],and significant higher high density lipoprotein cholesterol(HDL-C)level[(3.12±0.93)mmol/L vs.(4.10±1.00)mmol/L](P＜0.001 all).Incidence of adverse reactions(13.85％vs.33.85％)and poor prognosis(26.15％vs.55.38％)in com-bined treatment group were significantly lower than those of control group(P＜0.01 both).Conclusion:Recombi-nant human brain natriuretic peptide combined with sacubitril valsartan may improve blood lipid levels and hemody-namics,reduce incidence of poor prognosis with significant effects in patients with coronary heart disease and heart failure.
